---
sidebar_position: 4
---

# Target Discovery & Validation Agent

Evaluate any gene target for drug discovery — from biology to competitive landscape — in one run.

---

## What It Does

This agent generates enterprise-ready target assessment dossiers by integrating biology, safety genetics, druggability, and competitive context. Give it a gene name, and it produces a structured 10-section report covering everything a drug discovery team needs to make a go/no-go decision.

- **Genetics evidence** — GWAS, ClinVar, COSMIC data ranked by strength
- **Target biology** — function, pathways, disease mechanisms
- **Preclinical validation** — cell and in vivo model evidence
- **Clinical proof of concept** — efficacy and safety signals from trials
- **Competitive landscape** — all known molecules in development, with status
- **Strategic assessment** — modality fit, patient population, opportunity analysis

---

## The Story: A Drug Discovery Scientist's Checklist Becomes an Agent

### The Prompt

```
I need to create an agent for disease agnostic target assessment.

I am considering [gene x] as a new target. Can you provide:
1. Human genetics/cancer genomics data, ranked strongest to weakest
2. Target biology including function, pathway, disease biology
3. Target validation preclinically in cell and in vivo
4. Clinical proof of concept data
5. Safety of preclinical and clinical data
6. Targeted patient population including size and biomarker
7. Competitive landscape of all known molecules in development
   — compound name, company, stage, and whether still active
8. What is the right modality to match the target mechanism
9. Whether there is opportunity for a new compound
10. Key challenges to bring a new discovery program forward
```

This is exactly how pharma scientists evaluate targets — a structured 10-point checklist. The user pasted it in as-is and MorphMind turned it into a multi-step research agent.

### What MorphMind Built

A 7-step pipeline that queries real biomedical databases and synthesizes findings into a structured dossier:

1. **Genetics Evidence** — searches GWAS, ClinVar, and COSMIC; ranks associations by statistical significance and replication
2. **Target Biology** — extracts function and pathway data from UniProt and literature
3. **Validation Data** — searches PubMed for cell and in vivo model studies
4. **Clinical Evidence** — queries ClinicalTrials.gov and PubMed for efficacy and safety signals
5. **Competitive Landscape** — maps all molecules in development with compound, company, stage, and active status
6. **Strategic Assessment** — synthesizes epidemiology, modality fit, opportunity gaps, and risks
7. **PDF Report** — generates a formatted 10-section assessment document with inline citations

---

## Why This Matters

**Target assessment typically takes a team weeks. This agent does it in minutes.** A typical pharma target assessment involves a scientist manually querying 5–10 databases, reading dozens of papers, and assembling a report. This agent automates the entire workflow — and maintains a consistent, auditable structure every time.

| Traditional Approach | Agent Approach |
|----------------------|----------------|
| Manually query GWAS, ClinVar, COSMIC | Automated search with ranked results |
| Read 30+ papers for validation evidence | Systematic PubMed search and synthesis |
| Compile competitive landscape from trial registries | Live ClinicalTrials.gov query with status verification |
| Write report over 1–2 weeks | Structured dossier generated in one run |

### Bring Any Data Source — Public or Private

Out of the box, this agent queries live public databases: [Europe PMC](https://europepmc.org) for literature, [Open Targets](https://platform.opentargets.org) for genetics-to-disease associations, [gnomAD](https://gnomad.broadinstitute.org) for safety genetics, and [ChEMBL](https://www.ebi.ac.uk/chembl/) for bioactivity data.

But you're not limited to these. **Users can arbitrarily add any data source — public or proprietary** — through conversation. Want to connect your company's internal target database or a licensed dataset? Just tell the agent:

```
Use this API key for our internal compound registry: sk-...
Also add the Pharmaprojects database with this token.
```

The agent handles the integration. No configuration files, no code changes — just say which source to use and provide the credentials. This means the same agent works for an academic lab using only public databases and for a pharma team layering in proprietary competitive intelligence.

---

## Getting Started

[**Open Target Discovery & Validation Agent →**](https://agentlab.morphmind.ai/shared/8xy8d5yx)

### Quick Actions

| Action | What It Does |
|--------|-------------|
| **Assess a new target** | Full 10-section dossier for any gene target |
| **Check safety genetics** | Screen a target for safety signals (gnomAD, clinical data) |
| **Analyze the competition** | Map all molecules in development for a target or indication |

### Example Prompts

```
Assess BRAF as a cancer target. Provide the full 10-section evaluation.
```

```
What is the competitive landscape for TP53-targeting therapies?
Include compound name, company, stage, and whether the program is still active.
```

```
Evaluate WRN as a synthetic lethal target in MSI-high cancers.
What modality fits best?
```

---

## Report Quality

The agent was refined with specific guidelines for output quality:

- **Discovery scientist voice** — balanced, evidence-based, acknowledging uncertainties (not company-presentation tone or investment-report tone)
- **Structured sections** — Executive Summary → Target Biology → Indications → Competitive Landscape → Strategic Recommendation
- **Inline citations** — every claim linked to its source
- **Concise reports** — 2,000–3,000 words with bullet points for data-heavy sections

---

## Key Takeaway

> **Paste your domain's evaluation checklist and the agent builds itself.** The 10-point target assessment framework used by pharma scientists became a working research agent — complete with live database queries, competitive mapping, and structured PDF output.
